TIL MT Newswires 6 days ago Instil Bio Says Subsidiary Decided to Discontinue Clinical Development of AXN-2510; Shares Fall Pre-Bell ๐ AI Sentiment Negative 2/10
TIL GlobeNewswire 6 days ago Instil Bioโs Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco ๐ AI Sentiment Negative 2/10